点击蓝字，关注我们核心观点事件：巨子生物发布2025年半年度报告。25H1公司实现营收31.13亿元(yoy+22.52%)；实现经调整净利润12.05亿元（yoy+17.39%）。25H1营收同比+22.52%，可复美、可丽金收入增长亮眼。2025年上半年，公司实现收入31.13亿元，同比+22.52%。25H1收入分业务来看：1）专业皮肤护理产品，25H1收入为31.03亿元，同比+...
Source Link点击蓝字，关注我们核心观点事件：巨子生物发布2025年半年度报告。25H1公司实现营收31.13亿元(yoy+22.52%)；实现经调整净利润12.05亿元（yoy+17.39%）。25H1营收同比+22.52%，可复美、可丽金收入增长亮眼。2025年上半年，公司实现收入31.13亿元，同比+22.52%。25H1收入分业务来看：1）专业皮肤护理产品，25H1收入为31.03亿元，同比+...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.